Endothelin receptor inhibition with bosentan delays onset of liver injury in streptozotocin-induced diabetic condition.

DEMIRCI, Elif; FERAH, Irmak; GUNDOGDU, C; OZKANLAR, Seçkin; BAYGUTALP, Nurcan; Bayir, Yasin; CALIK, Muhammet; AYAZ, G

doi:10.1055/s-0034-1377024

Endothelin receptor inhibition with bosentan delays onset of liver injury in streptozotocin-induced diabetic condition.

DEMIRCI E., FERAH I., GUNDOGDU C., OZKANLAR S., BAYGUTALP N., Bayir Y., ...Daha Fazla

Drug research, cilt.65, sa.5, ss.272-80, 2015 (Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 5
Basım Tarihi: 2015
Doi Numarası: 10.1055/s-0034-1377024
Dergi Adı: Drug research
Derginin Tarandığı İndeksler: Scopus
Sayfa Sayıları: ss.272-80
Anahtar Kelimeler: diabetes, liver, endothelin, cytokines, oxidative stress, rat, GROWTH-FACTOR-BETA, MESENTERIC-ARTERIES, VASCULAR SUPEROXIDE, RENAL-DISEASE, INSULIN, EXPRESSION, BLOCKADE, TYPE-1, CELLS, HYPERTENSION
Atatürk Üniversitesi Adresli: Evet

Özet

Background: This study was designed to investigate the protective effects of bosentan an orally active non-peptide mixed ETA/ETB receptor antagonist, on liver injury in streptozotocin-induced diabetic rats.